PROCAINAMIDE DISPOSITION IN OBESITY

被引：34

作者：

CHRISTOFF, PB

CONTI, DR

NAYLOR, C

JUSKO, WJ

机构：

[1] SUNY BUFFALO,SCH PHARM,DIV CLIN PHARM SCI,BUFFALO,NY 14260

[2] SUNY BUFFALO,SCH PHARM,DEPT PHARMACEUT,BUFFALO,NY 14260

[3] MILLARD FILLMORE HOSP,BUFFALO,NY 14209

来源：

DRUG INTELLIGENCE & CLINICAL PHARMACY | 1983年 / 17卷 / 7-8期

关键词：

D O I：

10.1177/106002808301700704

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：516 / 522

页数：7

共 36 条

[11] ESTIMATING CREATININE CLEARANCE IN MORBIDLY OBESE PATIENTS
DIONNE, RE
BAUER, LA
GIBSON, GA
GRIFFEN, WO
BLOUIN, RA
[J]. AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1981, 38 (06): : 841 - 844
[12] ANTIARRHYTHMIC POTENCY OF N-ACETYLPROCAINAMIDE
ELSON, J
STRONG, JM
LEE, WK
ATKINSON, AJ
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1975, 17 (02) : 134 - 140
[13] DIGOXIN METABOLISM IN OBESITY
EWY, GA
GROVES, BM
BALL, MF
NIMMO, L
JACKSON, B
MARCUS, F
[J]. CIRCULATION, 1971, 44 (05) : 810 - +
[14] GAL P, 1978, CLIN PHARMACOL THER, V23, P438
[15] GALEAZZI RL, 1975, CLIN PHARMACOL THER, V19, P55
[16] A QUANTITATIVE APPROACH TO BIOCHEMICAL STRUCTURE-ACTIVITY RELATIONSHIPS
HANSCH, C
[J]. ACCOUNTS OF CHEMICAL RESEARCH, 1969, 2 (08) : 232 - &
[17] Jusko WJ, 1980, APPLIED PHARMACOKINE, P639
[18] CORONARY HEART-DISEASE - OVERWEIGHT AND OBESITY AS RISK FACTORS
KEYS, A
KARVONEN, MJ
MENOTTI, A
VANBUCHE.FS
TAYLOR, HL
PUDDU, V
BUZINA, R
BLACKBURN, H
ARAVANIS, C
DJORDJEVIC, BS
FIDANZA, F
[J]. ANNALS OF INTERNAL MEDICINE, 1972, 77 (01) : 15 - +
[19] PROCAINAMIDE DOSAGE SCHEDULES, PLASMA CONCENTRATIONS, AND CLINICAL EFFECTS
KOCHWESER, J
KLEIN, SW
[J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1971, 215 (09) : 1454 - +
[20] THE EFFECT OF OBESITY ON ACETAMINOPHEN PHARMACOKINETICS IN MAN
LEE, WH
KRAMER, WG
GRANVILLE, GE
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 21 (07) : 284 - 287